No connection

Search Results

AXSM vs TEM

AXSM
Axsome Therapeutics, Inc.
BEARISH
Price
$185.96
Market Cap
$9.37B
Sector
Healthcare
AI Confidence
68%
TEM
Tempus AI, Inc.
BEARISH
Price
$56.78
Market Cap
$10.19B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
AXSM
--
TEM
--
Forward P/E
AXSM
423.03
TEM
-628.03
P/B Ratio
AXSM
126.85
TEM
20.58
P/S Ratio
AXSM
16.7
TEM
8.01
EV/EBITDA
AXSM
-49.31
TEM
-62.52

Profitability

Gross Margin
AXSM
91.86%
TEM
62.74%
Operating Margin
AXSM
-19.25%
TEM
-16.7%
Profit Margin
AXSM
-40.89%
TEM
-19.27%
ROE
AXSM
-275.5%
TEM
-89.48%
ROA
AXSM
-19.79%
TEM
-9.66%

Growth

Revenue Growth
AXSM
63.2%
TEM
83.0%
Earnings Growth
AXSM
--
TEM
--

Financial Health

Debt/Equity
AXSM
2.96
TEM
2.7
Current Ratio
AXSM
1.57
TEM
3.13
Quick Ratio
AXSM
1.45
TEM
2.88

Dividends

Dividend Yield
AXSM
--
TEM
--
Payout Ratio
AXSM
0.0%
TEM
0.0%

AI Verdict

AXSM BEARISH

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of just 3/9, indicating significant operational and profitability concerns. Despite strong revenue growth of 63.2% and a bullish analyst recommendation, the company is deeply unprofitable with a -40.89% profit margin, negative ROE of -275.50%, and a high debt/equity ratio of 2.96. Valuation metrics are stretched, with a forward P/E of 423x and a price-to-book of 126.85, while insider selling of $85.54M in the last six months signals strong bearish sentiment from management. Although the stock has delivered impressive price performance over the past year (+79%), these gains appear disconnected from fundamentals, increasing vulnerability to downside correction.

Strengths
Exceptional year-over-year revenue growth of 63.20%, significantly above sector average of 39.78%
High gross margin of 91.86%, indicating strong pricing power and low cost of goods sold
Analyst consensus is strong_buy with a target price of $210.19, implying 13% upside
Risks
Piotroski F-Score of 3/9 indicates weak financial health and poor profitability trends
Extremely high forward P/E of 423x with no Graham Number, suggesting severe overvaluation relative to earnings
Negative ROE of -275.50% and negative operating margins signal deep profitability issues
TEM BEARISH

Tempus AI exhibits critical financial fragility, highlighted by a Piotroski F-Score of 1/9, indicating severe weakness across profitability and operational efficiency. While the company demonstrates explosive revenue growth of 83% YoY, this is offset by deep negative margins and a high Debt/Equity ratio of 2.70. The bearish outlook is further reinforced by aggressive insider selling, including significant divestments by the CEO and CFO, and a technical trend score of 0/100. Despite analyst optimism, the fundamental health metrics suggest a high-risk profile.

Strengths
Exceptional YoY revenue growth of 83.00%
Strong Q/Q revenue growth of 82.98%
Healthy liquidity with a Current Ratio of 3.13
Risks
Critical financial health (Piotroski F-Score 1/9)
Heavy insider selling totaling $43.97M with zero insider buys
High leverage with a Debt/Equity ratio of 2.70

Compare Another Pair

AXSM vs TEM: Head-to-Head Comparison

This page compares Axsome Therapeutics, Inc. (AXSM) and Tempus AI, Inc. (TEM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile